Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2023-04-20 00:00:00 ET · period of report 2023-04-17 · accession 0001209191-23-024939 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-20 | 2023-04-17 | ORMP | KIDRON NADAV | Pres, CEO, Dir | A - Grant | — | +279.0K | 1.33M | +26% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-17 | A | A | 279,000 | — | 1,332,098 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 23,250 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |